Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: Disease overview • Disease overview PART 06: Key clinical trials PART 07: Market dynamics PART 08: Market landscape • Market overview • Five forces analysis PART 09: Market segmentation by drug-class • Global calcium channel blockers market • Global beta-adrenergic blockers market • Global antiarrhythmic market • Global anticoagulants market PART 10: Geographical segmentation • HCM therapeutics market in Americas • HCM therapeutics market in EMEA • HCM therapeutics market in APAC PART 11: Decision framework PART 12: Drivers and challenges • Market drivers • Market challenges • Impact of drivers and challenges on key customer segments (hospitals and pharmacies) PART 13: Market trends • Increasing availability of genetic tests • Development of TBI • Advent of genomic medicine PART 14: Vendor landscape • Competitive landscape PART 15: Key vendor analysis • AstraZeneca • Merck • Pfizer • Sanofi • Other prominent vendors PART 16: Appendix • List of abbreviations List of Exhibits Exhibit 01: Types of HCM Exhibit 02: Treatment for HCM Exhibit 03: Snapshot of HCM therapeutics pipeline 2016 Exhibit 04: Pipeline analysis for HCM therapeutics market Exhibit 05: Mutation Exhibit 06: Identification of pathogenicity in genes by genetic testing Exhibit 07: Global HCM therapeutics market snapshot Exhibit 08: Global HCM therapeutics market 2016-2021 ($ millions) Exhibit 09: Opportunity analysis in global HCM therapeutics market Exhibit 10: Five forces analysis Exhibit 11: Market segmentation based on drug class Exhibit 12: Global calcium channel blockers market 2016-2021 ($ millions) Exhibit 13: Global beta-adrenergic blockers market 2016-2021 ($ millions) Exhibit 14: Global antiarrhythmic market 2016-2021 ($ millions) Exhibit 15: Global anticoagulants market 2016-2021 ($ millions) Exhibit 16: Global HCM therapeutics market by geography 2016 and 2021 Exhibit 17: Global HCM therapeutics market by geography 2016-2021 ($ millions) Exhibit 18: Market scenario in Americas Exhibit 19: HCM therapeutics market in Americas 2016-2021 ($ millions) Exhibit 20: Market scenario in EMEA Exhibit 21: HCM therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 22: Market scenario in APAC Exhibit 23: HCM therapeutics market in APAC 2016-2021 ($ millions) Exhibit 24: Prevalence of obesity among US adults 2015 Exhibit 25: Impact of drivers and challenges Exhibit 26: Group of HCM individuals based on genetic tests Exhibit 27: Competitive structure analysis of global HCM therapeutics market 2016 Exhibit 28: AstraZeneca: Key highlights Exhibit 29: AstraZeneca: Strength assessment Exhibit 30: AstraZeneca: Strategy assessment Exhibit 31: AstraZeneca: Opportunity assessment Exhibit 32: Merck: Key highlights Exhibit 33: Merck: Strength assessment Exhibit 34: Merck: Strategy assessment Exhibit 35: Merck: Opportunity assessment Exhibit 36: Pfizer: Key highlights Exhibit 37: Pfizer: Strength assessment Exhibit 38: Pfizer: Strategy assessment Exhibit 39: Pfizer: Opportunity assessment Exhibit 40: Sanofi: Key highlights Exhibit 41: Sanofi: Strength assessment Exhibit 42: Sanofi: Strategy assessment Exhibit 43: Sanofi: Opportunity assessment

AstraZeneca, Merck, Pfizer, Sanofi, Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.